Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Final Report of a Trial of Intensive versus Standard Blood-Pressure Control

Open access
The SPRINT Research Group·2021·New England Journal of Medicine

Abstract

BACKGROUND: In a previously reported randomized trial of standard and intensive systolic blood-pressure control, data on some outcome events had yet to be adjudicated and post-trial follow-up data had not yet been collected. METHODS: We randomly assigned 9361 participants who were at increased risk for cardiovascular disease but did not have diabetes or previous stroke to adhere to an intensive treatment target (systolic blood pressure, <120 mm Hg) or a standard treatment target (systolic blood pressure, <140 mm Hg). The primary outcome was a composite of myocardial infarction, other acute coronary syndromes, stroke, acute decompensated heart failure, or death from cardiovascular causes. Additional primary outcome events occurring through the end of the intervention period (August 20, 2015) were adjudicated after data lock for the primary analysis. We also analyzed post-trial observational follow-up data through July 29, 2016. RESULTS: At a median of 3.33 years of follow-up, the rate of the primary outcome and all-cause mortality during the trial were significantly lower in the intensive-treatment group than in the standard-treatment group (rate of the primary outcome, 1.77% per year vs. 2.40% per year; hazard ratio, 0.73; 95% confidence interval [CI], 0.63 to 0.86; all-cause mortality, 1.06% per year vs. 1.41% per year; hazard ratio, 0.75; 95% CI, 0.61 to 0.92). Serious adverse events of hypotension, electrolyte abnormalities, acute kidney injury or failure, and syncope were significantly more frequent in the intensive-treatment group. When trial and post-trial follow-up data were combined (3.88 years in total), similar patterns were found for treatment benefit and adverse events; however, rates of heart failure no longer differed between the groups. CONCLUSIONS: Among patients who were at increased cardiovascular risk, targeting a systolic blood pressure of less than 120 mm Hg resulted in lower rates of major adverse cardiovascular events and lower all-cause mortality than targeting a systolic blood pressure of less than 140 mm Hg, both during receipt of the randomly assigned therapy and after the trial. Rates of some adverse events were higher in the intensive-treatment group. (Funded by the National Institutes of Health; SPRINT ClinicalTrials.gov number, NCT01206062.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa1901281

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 20 references

Cited by

See all 462

Metadata

Authors
The SPRINT Research Group
Affiliations
National Institutes of Health (US)
Corresponding author
The SPRINT Research Group
Venue
New England Journal of Medicine
Published
2021-05-20
Volume
384
Issue
20
Pages
1921-1930
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3161638097
Cited by
454
References
20
Citations by year
2026: 74 · 2025: 92 · 2024: 74 · 2023: 83 · 2022: 105 · 2021: 26
FWCI
48.27
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health, National Heart, Lung, and Blood Institute
  • National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
  • NIH, National Institute on Aging
  • NIH, National Institute of Neurological Disorders and Stroke
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
Keywords
intensive blood pressure control, systolic blood pressure target, antihypertensive therapy, major adverse cardiovascular events, all-cause mortality, cardiovascular risk, adverse events, acute kidney injury, heart failure, post-trial follow-up, SPRINT trial, acute coronary syndrome, stroke, myocardial infarction, syncope, electrolyte imbalance, hypotension
MeSH terms
Aged, Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Female, Follow-Up Studies, Humans, Hypertension, Male, Middle Aged

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. https://app.cochat.ai/papers/10.1056/nejmoa1901281
The paper
The SPRINT Research Group. (2021). Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1901281

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.